Skip to main content
Premium Trial:

Request an Annual Quote

Eurogentec Reaches Deal to Buy AnaSpec

NEW YORK (GenomeWeb News) – Eurogentec said today that it has reached an agreement to acquire proteomics company AnaSpec for an undisclosed sum.

The agreement will give Eurogentec the potential to offer both genomics and proteomics tools for biotech, pharmaceutical, and diagnostics markets, the company said.

AnaSpec, based in Fremont, Calif., provides integrated proteomics solutions and specializes in peptide synthesis, labeled peptides and antibodies, fluorescent dyes, enzymatic activities, and assays for basic research, high-throughput screening, and drug discovery.

Eurogentec said it plans to maintain AnaSpec's facility and employees in Fremont, and that AnasSpec's co-founders, President Anita Hong and CEO Frank Hong, will remain with the company in leading roles.

Eurogentec CEO Jean-Pierre Delwart said in a statement that the deal "considerably strengthens Eurogentec's geographical presence in the US," and the company will market and support AnaSpec's products in Europe.

Financial terms of the agreement were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more